Cambrex Corporation

177 articles with Cambrex Corporation

• Cambrex to Invest $50 Million to Expand Multipurpose Large-Scale Manufacturing Capabilities in the U.S.

  11/17/2020

  The expansion, which will be operational in early 2022, will increase API manufacturing capacity to meet current customer needs and support growing demand within the industry

• Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh

  10/12/2020

  Cambrex, announced the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.

• Cambrex Increases Flexible Manufacturing Capacity at Karlskoga, Sweden Facility

  7/1/2020

  Cambrex, the leading small molecule company providing drug substance, drug product, and analytical services across the entire drug lifecycle, announced that it is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity.

• Cambrex Names Thomas Loewald as Chief Executive Officer

  6/18/2020

  Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced that Tom Loewald has been named Chief Executive Officer and a member of the company’s Board of Directors, effective September 7th.

• Cambrex Announces Management Transitions

  6/2/2020

  CEO Steven Klosk to Retire, President Shawn Cavanagh to Become Strategic Advisor to the Company Cambrex in Advanced Stages of Search for CEO Successor EAST RUTHERFORD, N.J.--( BUSINESS WIRE )-- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Steven Klosk will retire as Chief Executive Officer and member of the Board of Directors on

• Cambrex Appoints Troy Player as President, Early Stage Development & Testing Business Unit

  3/31/2020

  Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced that Troy Player has been appointed as President, Early Stage Development and Testing.

• Cambrex Announces Management Changes and Board Appointments

  1/6/2020

  The following appointments and new positions are effective immediately.

• Cambrex Announces Completion of Acquisition by the Permira Funds

  12/4/2019

  Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced the completion of its previously announced sale to an affiliate of the Permira funds.

• Cambrex (CBM) Alert: Johnson Fistel Investigates Proposed Sale of Cambrex Corporation; Is $60 a Fair Price?

  8/7/2019

  Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Cambrex Corporation breached their fiduciary duties in connection with the proposed sale of the Company to private equity firm Permira.

• 

  Permira Snaps Up Cambrex in Deal Valued at $2.4 Billion

  8/7/2019

  Permira initiated the transaction after Cambrex flexed its own M&A muscle and acquired Avista and Halo.

• Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results

  2/8/2018

  Net revenue increased 2.5% to $182.3 million compared to $177.9 million in the same quarter last year.

• Cambrex to Announce Fourth Quarter and Full Year 2017 Financial Results on February 8, 2018

  2/2/2018

  The Company will host a conference call to discuss the financial results.

• Cambrex Expands Process Research and Development Capabilities Across North America

  1/30/2018

  The project forms part of the company’s strategic plan to increase its development capacity and resources in North America.

• Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility

  1/16/2018

  The companies held an opening ceremony to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.

• Cambrex Invests in New Small Scale Capacity at Its Charles City, Iowa Facility

  11/8/2017

  The project has seen the installation of two 500 gallon glass lined reactors and creates a third small scale work center, further increasing flexibility for customer projects.

• Cambrex Reports Third Quarter 2017 Financial Results

  11/7/2017

  Net Revenue increased 13% to $112.6 million compared to $99.4 million in the same quarter last year.

• Gregory B. Brown M.D. Appointed to the Board of Directors of Cambrex Corporation

  11/3/2017

  Dr. Brown’s appointment increases the size of the Board to ten members.

• Cambrex to Announce Third Quarter 2017 Financial Results on November 7, 2017

  11/1/2017

  The Company will host a conference call to discuss the financial results.

• Cambrex Adds Large Scale Manufacturing Capacity at Its Charles City, Iowa Facility

  10/23/2017

  The new reactors have been installed in the 7,500 sq. ft. multi-purpose manufacturing facility which opened at the site in 2016.

• Cambrex Corporation Invests In Generic API Development And Manufacturing Capabilities At Its Milan Site

  10/12/2017